Company / Accounts Receivable
Tango Therapeutics, Inc. Accounts Receivable History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.0M
FY2022
5-year range
$2.0M / $2.0M
FY2020-FY2022
Trend
+0.0%
vs FY2021
Sector context
#103 of 113
Health Care
What the data says
Among 113 Health Care companies, Tango Therapeutics, Inc. is in the bottom 9% for accounts receivable. Accounts Receivable remained relatively stable over the past 3 years, with values between $2M and $2M.
Based on SEC 10-K filings.
$2M in FY2022.
Remained stable around $2M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 113This company $2.0M Sector average $1.1B
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2022, accounts receivable increased 0.0% year-over-year.
- Ranks #103 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $2.0M | +0.0% |
| FY2021 | $2.0M | +0.0% |
| FY2020 | $2.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026